Severe liver injury was also reported in patients with CML treated with nilotinib and dasatinib.10,11 However, among several studies comparing imatinib with the other BCR-ABL TKIs,12,13,14,15,16,17,18,19 only one mentions hepatic effects without stratification study.19 Hence, it is necessary to perform a meta-analysis focusing specifically on the relative risk of hepatotoxicity associated with each BCR-ABL TKI. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.